自体树突状细胞瘤苗免疫治疗晚期肝癌。
Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC.
机构信息
Department of Clinical Pathology, Kasr Al-Aini, Cairo University, Cairo, Egypt.
出版信息
J Cancer Res Clin Oncol. 2013 Jan;139(1):39-48. doi: 10.1007/s00432-012-1298-8. Epub 2012 Aug 12.
BACKGROUND
Dendritic cells (DCs) could be used as potential cellular adjuvant for the production of specific tumor vaccines.
OBJECTIVES
Our study was aimed to evaluate the safety and efficacy of autologous pulsed DC vaccine in advanced hepatocellular carcinoma (HCC) patients in comparison with supportive treatment.
METHODS
Thirty patients with advanced HCC not suitable for radical or loco-regional therapies were enrolled. Patients were divided into 2 groups, group I consisted of 15 patients received I.D vaccination with mature autologous DCs pulsed ex vivo with a liver tumor cell line lysate. Group II (control group, no. 15) received supportive treatment. One hundred and 4 ml of venous blood were obtained from each patient to generate DCs. DCs were identified by CD80, CD83, CD86 and HLA-DR expressions using flow cytometry. Follow up at 3, and 6 months post injection by clinical, radiological and laboratory assessment was done.
RESULTS
Improvement in overall survival was observed. Partial radiological response was obtained in 2 patients (13.3 %), stable course in 9 patients (60 %) and 4 patients (26.7 %) showed progressive disease (died at 4 months post-injection). Both CD8(+) T cells and serum interferon gamma were elevated after DCs injection.
CONCLUSION
Autologous DC vaccination in advanced HCC patients is safe and well tolerated.
背景
树突状细胞（DC）可作为产生特定肿瘤疫苗的潜在细胞佐剂。
目的
本研究旨在评估自体脉冲化 DC 疫苗在晚期肝细胞癌（HCC）患者中的安全性和疗效，并与支持性治疗进行比较。
方法
30 例不适合根治性或局部区域治疗的晚期 HCC 患者入组。患者分为两组，组 I 由 15 例患者组成，接受成熟的自体 DC 免疫接种，这些 DC 是通过体外与肝癌细胞裂解物共培养而被激活的。组 II（对照组，n=15）接受支持性治疗。从每位患者中采集 104ml 静脉血以生成 DC。通过流式细胞术检测 CD80、CD83、CD86 和 HLA-DR 的表达来鉴定 DC。在注射后 3 个月和 6 个月进行临床、影像学和实验室评估。
结果
观察到总生存的改善。2 例患者（13.3%）获得部分影像学缓解，9 例（60%）病情稳定，4 例（26.7%）疾病进展（在注射后 4 个月死亡）。DC 注射后 CD8(+) T 细胞和血清干扰素γ均升高。
结论
晚期 HCC 患者自体 DC 疫苗接种安全且耐受良好。
Zotero 插件